Cobimetinib - Genentech/Exelixis
Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518Latest Information Update: 28 Aug 2024
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis; Genentech; InxMed; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
- Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma
- Registered Histiocytosis
- Phase III Colorectal cancer
- Phase II Brain metastases; Breast cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer; Urogenital cancer; Vascular disorders
- Phase I/II Multiple myeloma; Pancreatic cancer; Solid tumours
- No development reported Acute myeloid leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uveal melanoma
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy (PO)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (PO)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)